Symposium 2025 Recordings

Living the digital transformation in a biotech company 

Dr. Dietmar Lang

Abstract

The introduction of digital twins in the pharmaceutical industry marks a significant leap towards Pharma 4.0, particularly for biotech companies like CureVac.

Digital twins, which are virtual replicas of physical entities, enable real-time simulation and analysis of mRNA, antibody and other drug development processes. This technology, in combination with real time analytics, will enhance quality control for the process and product, will facilitate the optimization of production processes and will consequently accelerate time-to-market for new drugs / drug modalities. The implementation of digital twins aligns with the principles of Pharma 4.0, which emphasizes the integration of digital technologies into all aspects of pharmaceutical manufacturing. Leveraging these tools might enhance, streamline and accelerating bioprocessing, and foster innovation for the bespoke modality areas.

In conclusion, digital twins represent a transformative tool for biotech and pharma companies, enabling a seamless transition towards Pharma 4.0, rewarded by gaining quality, financial benefit at less time needed for their drug products’ production.